Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer
Author:
Funder
AstraZeneca
Publisher
Elsevier BV
Subject
Obstetrics and Gynaecology,Oncology
Reference44 articles.
1. Cancer statistics, 2014;Siegel;CA Cancer J. Clin.,2014
2. Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients;Monk;Curr. Pharm. Des.,2016
3. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials;Foster;Cancer,2011
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials;Endokrynologia Polska;2023-02-27
2. Targeting ovarian cancer stem cells: a new way out;Stem Cell Research & Therapy;2023-02-14
3. Efficacy of non‑platinum chemotherapy in platinum‑resistant ovarian cancer: a meta‑analysis;Malignant tumours;2022-04-08
4. Significance of emerging clinical oncology endpoints in support of overall survival;Indian Journal of Cancer;2022
5. Surrogate Endpoints in Oncology: Overview of Systematic Reviews and Their Use for Health Decision Making in Mexico;Value in Health Regional Issues;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3